Urology · Chambersburg, PA
NPI
1790733798
Since 2006
Specialty
Urology
Code 208800000X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
120 N 7th St Ste 200
Chambersburg, PA, 17201
Phone (717) 217-6803
Groups this clinician bills Medicare through
Medicare paid, 2024
$419K
15,611 services
Medicare patients, 2024
1,756
Average age 76
Drug cost, 2024
$1.0M
7,840 prescriptions
Company payments, 2025
$15.85
From 1 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Louis L Glass was code J0585 (injection, onabotulinumtoxina, 1 unit), 4,750 times for 23 patients. In total Louis L Glass billed 15,611 services in 78 codes, and Medicare paid $419K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-06-05.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0585 Injection, onabotulinumtoxina, 1 unit | Office | 4,750 | 23 | $4.82 | $23K |
| J9155 Injection, degarelix, 1 mg | Office | 3,240 | 14 | $3.33 | $11K |
| J9030 Bcg live intravesical instillation, 1 mg | Office | 2,002 | 11 | $2.21 | $4,433 |
| 99213 Office E&M - Established | Office | 1,328 | 1,109 | $58.55 | $78K |
| 99214 Office E&M - Established | Office | 717 | 536 | $89.21 | $64K |
| J9217 Leuprolide acetate (for depot suspension), 7.5 mg | Office | 462 | 56 | $138.50 | $64K |
| 81003 Clinical Chemistry | Office | 454 | 395 | $2.19 | $993 |
| 51798 Ultrasound - Nonspecific | Office | 449 | 359 | $7.61 | $3,417 |
| 99204 Office E&M - New | Office | 159 | 159 | $113.33 | $18K |
| 52000 Cystourethroscopy | Office | 144 | 122 | $169.14 | $24K |
| 99203 Office E&M - New | Office | 137 | 137 | $69.82 | $9,565 |
| 96402 Chemotherapy Administration | Office | 124 | 58 | $25.71 | $3,188 |
| 99212 Office E&M - Established | Office | 114 | 111 | $35.26 | $4,019 |
| 74420 Standard X-ray | Facility | 86 | 68 | $18.34 | $1,577 |
| 51720 Chemotherapy Administration | Office | 47 | 13 | $63.37 | $2,978 |
By year: 2022 $353K for 12,127 services; 2023 $351K for 13,075 services; 2024 $419K for 15,611 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 81003 Clinical Chemistry | 454 | 395 | $2.19 | $993 |
Medicare prescription drug claims, 2024
In 2024, the drug Louis L Glass prescribed most often to Medicare patients was Tamsulosin Hcl, with 2,398 prescriptions and refills. In total Louis L Glass wrote 7,840 Medicare prescriptions that cost $1.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Tamsulosin Hcl Generic | 2,398 | 5,978 | 689 | $49K |
| Finasteride Generic | 1,790 | 4,927 | 513 | $26K |
| Amitriptyline Hcl Generic | 535 | 1,023 | 139 | $6,723 |
| Solifenacin Succinate Generic | 351 | 656 | 107 | $11K |
| Myrbetriq Mirabegron | 286 | 426 | 61 | $186K |
| Potassium Citrate Er Potassium Citrate | 226 | 542 | 61 | $26K |
| Hydrochlorothiazide Generic | 217 | 496 | 51 | $398 |
| Oxybutynin Chloride Er Oxybutynin Chloride | 193 | 483 | 56 | $8,242 |
| Bicalutamide Generic | 176 | 293 | 43 | $4,522 |
| Levofloxacin Generic | 119 | 119 | 106 | $411 |
| Doxazosin Mesylate Generic | 116 | 324 | 30 | $2,348 |
| Dutasteride Generic | 110 | 315 | 35 | $4,507 |
| Cephalexin Generic | 105 | 113 | 79 | $390 |
| Potassium Chloride Generic | 101 | 223 | 27 | $5,616 |
| Methenamine Hippurate Generic | 97 | 185 | 24 | $6,770 |
Brand drugs: - claims; generic drugs: 7,398 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Louis L Glass $15.85 ($15.85 in general payments such as food, travel and fees) from 1 company. The largest payer was Astellas Pharma US Inc with $15.85.
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc 4503.T | 1 | $15.85 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.